FME:XETRA-Fresenius Medical Care AG & Co. KGaA (EUR)

COMMON STOCK | Medical Care Facilities | XETRA

Last Closing Price

EUR 29.66

Change

-0.13 (-0.44)%

Market Cap

EUR 8.70B

Volume

0.45M

Avg Analyst Target

EUR 38.59 (+30.11%)

Avg User Target

EUR
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


FME Stock Forecast & Price:
Based on the Fresenius Medical Care AG & Co. KGaA stock forecasts from 9 analysts, the average analyst target price for Fresenius Medical Care AG & Co. KGaA is EUR 38.59 over the next 12 months. Fresenius Medical Care AG & Co. KGaA’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Fresenius Medical Care AG & Co. KGaA is Bullish , which is based on 7 positive signals and 3 negative signals. At the last closing, Fresenius Medical Care AG & Co. KGaA’s stock price was EUR 29.66. Fresenius Medical Care AG & Co. KGaA’s stock price has changed by +2.56% over the past week, +12.95% over the past month and -44.58% over the last year.

About Fresenius Medical Care AG & Co. KGaA (FME:XETRA)

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-11-29 )

Largest Industry Peers for Medical Care Facilities

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
FRE:XETRA Fresenius SE & Co. KGaA

+0.43 (+1.66%)

EUR14.80B 8.61 6.00
RHK:XETRA RHÖN-KLINIKUM Aktiengesellsch..

-0.05 (-0.33%)

EUR1.04B 34.67 8.21
MED:XETRA MEDICLIN Aktiengesellschaft

-0.20 (-5.68%)

EUR0.16B 15.73 4.59
V3V:XETRA VITA 34 AG

+0.02 (+0.25%)

EUR0.13B 82.25 -50.32
LIK:XETRA Limes Schlosskliniken AG

+4.00 (+1.14%)

EUR0.10B 24.25 12.69
M12:XETRA M1 Kliniken AG

+0.02 (+0.36%)

EUR0.10B 16.67 3.78
MAK:XETRA Maternus-Kliniken Aktiengesell..

N/A

EUR0.05B N/A 17.10

ETFs Containing FME

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Care Facilities)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -48.09% 25% F 6% F
Dividend Return 2.36% 100% A+ 56% F
Total Return -45.73% 38% F 6% F
Trailing 12 Months  
Capital Gain -43.80% 38% F 6% F
Dividend Return 2.56% 100% A+ 54% F
Total Return -41.25% 38% F 7% F
Trailing 5 Years  
Capital Gain -64.47% 14% F 6% F
Dividend Return 5.89% 100% A+ 33% F
Total Return -58.57% 14% F 7% F
Average Annual (5 Year Horizon)  
Capital Gain -11.88% 63% D 5% F
Dividend Return 1.31% 100% A+ 14% F
Total Return -10.57% 63% D 6% F
Risk Return Profile  
Volatility (Standard Deviation) 17.85% 75% C 48% F
Risk Adjusted Return -59.22% 63% D 8% F
Market Capitalization 8.70B 88% B+ 89% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Care Facilities)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 11.32 86% B 67% D+
Price/Book Ratio 0.58 100% A+ 90% A-
Price / Cash Flow Ratio 3.50 63% D 69% D+
EV/EBITDA 6.20 50% F 55% F
Management Effectiveness  
Return on Equity 6.66% 57% F 37% F
Return on Invested Capital 6.76% 63% D 47% F
Return on Assets 2.53% 63% D 46% F
Debt to Equity Ratio 47.55% 38% F 46% F
Technical Ratios  
Dividend Yield 4.51% 100% A+ 79% C+
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.90 50% F 74% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.